GSA Capital Partners LLP Invests $1.06 Million in Hologic, Inc. $HOLX

GSA Capital Partners LLP bought a new position in Hologic, Inc. (NASDAQ:HOLX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 15,658 shares of the medical equipment provider’s stock, valued at approximately $1,057,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HOLX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Hologic by 10.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock worth $2,395,000 after purchasing an additional 3,520 shares in the last quarter. Empowered Funds LLC increased its position in shares of Hologic by 27.7% in the first quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock worth $1,081,000 after acquiring an additional 3,790 shares in the last quarter. Ethic Inc. lifted its holdings in shares of Hologic by 127.5% during the 2nd quarter. Ethic Inc. now owns 10,200 shares of the medical equipment provider’s stock valued at $663,000 after acquiring an additional 5,717 shares in the last quarter. Carnegie Investment Counsel boosted its position in Hologic by 10.6% during the 2nd quarter. Carnegie Investment Counsel now owns 221,528 shares of the medical equipment provider’s stock worth $14,435,000 after purchasing an additional 21,273 shares during the period. Finally, AlTi Global Inc. increased its holdings in Hologic by 27.9% in the 2nd quarter. AlTi Global Inc. now owns 14,974 shares of the medical equipment provider’s stock valued at $986,000 after purchasing an additional 3,266 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on HOLX shares. Evercore cut Hologic from an “outperform” rating to an “in-line” rating and reduced their price objective for the stock from $79.00 to $78.00 in a research note on Monday, January 5th. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Weiss Ratings reissued a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Finally, Mizuho lowered shares of Hologic from an “outperform” rating to a “neutral” rating and lifted their price objective for the company from $70.00 to $78.00 in a research note on Thursday, October 23rd. Two research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $78.42.

Hologic Trading Down 0.1%

HOLX opened at $75.14 on Friday. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $75.36. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. The stock has a market capitalization of $16.77 billion, a PE ratio of 31.31, a P/E/G ratio of 2.24 and a beta of 0.72. The firm’s fifty day moving average price is $74.91 and its 200 day moving average price is $71.80.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.Hologic’s revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.87 earnings per share. As a group, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.